TITLE:
Effect of Rifapentine and Rifampicin on Anti-Tuberculosis
AUTHORS:
Weijia Lin, Yaping Zhang, Zhi Liu, Ping Feng, Zhihua Zhang, Xiulong Zhang
KEYWORDS:
Rifampicin, Rifapentine, Pulmonary Tuberculosis
JOURNAL NAME:
Journal of Tuberculosis Research,
Vol.9 No.3,
September
15,
2021
ABSTRACT: Objective: To investigate the clinical effect
of rifapentine and rifampicin in the treatment of pulmonary tuberculosis. Methods: Seventy-two cases of patients with initial treatment of pulmonary
tuberculosis who attended the First Hospital Affiliated to Hebei North University from February 2017 to August 2019 were selected. They were randomly divided into observation group and control
group, with 36 cases in each
group. The observation group was treated with isoniazid + rifapentine +
ethambutol, while the control group was treated with isoniazid + rifampicin +
ethambutol. The symptom relief, image absorption and adverse reactions were
compared between the two groups. Results: The rate of
symptom relief was 86.11% in the observation group and
94.44% in the control group, P . The lesion absorption rate was 77.79% in the
observation group and 88.89% in the control group, P Conclusion: Rifampicin is superior to
rifapentine in clinical symptom relief and lesion absorption, but the incidence
of adverse reactions is high.